Transgene Statistics

Total Valuation

Transgene has a market cap or net worth of GBP 200.85 million. The enterprise value is 213.30 million.

Market Cap	200.85M
Enterprise Value	213.30M

Important Dates

The next estimated earnings date is Tuesday, March 24, 2026.

Earnings Date	Mar 24, 2026
Ex-Dividend Date	n/a

Share Statistics

Current Share Class	273.83M
Shares Outstanding	n/a
Shares Change (YoY)	+30.91%
Shares Change (QoQ)	+0.10%
Owned by Insiders (%)	33.67%
Owned by Institutions (%)	n/a
Float	176.81M

Valuation Ratios

PE Ratio	n/a
Forward PE	n/a
PS Ratio	30.93
PB Ratio	-65.01
P/TBV Ratio	n/a
P/FCF Ratio	n/a
P/OCF Ratio	n/a
PEG Ratio	n/a

Financial Ratio History

Enterprise Valuation

EV / Earnings	-6.77
EV / Sales	32.32
EV / EBITDA	n/a
EV / EBIT	n/a
EV / FCF	-10.24

Financial Position

The company has a current ratio of 0.54

Current Ratio	0.54
Quick Ratio	0.46
Debt / Equity	n/a
Debt / EBITDA	n/a
Debt / FCF	-1.28
Interest Coverage	-17.59

Financial Efficiency

Return on Equity (ROE)	n/a
Return on Assets (ROA)	-49.35%
Return on Invested Capital (ROIC)	-71.16%
Return on Capital Employed (ROCE)	-4,406.32%
Weighted Average Cost of Capital (WACC)	7.62%
Revenue Per Employee	44,172
Profits Per Employee	-214,479
Employee Count	147
Asset Turnover	0.17
Inventory Turnover	n/a

Taxes

Income Tax	n/a
Effective Tax Rate	n/a

Stock Price Statistics

The stock price has increased by +17.65% in the last 52 weeks. The beta is 0.67, so Transgene's price volatility has been lower than the market average.

Beta (5Y)	0.67
52-Week Price Change	+17.65%
50-Day Moving Average	0.94
200-Day Moving Average	0.97
Relative Strength Index (RSI)	31.90
Average Volume (20 Days)	767

Short Selling Information

Short Interest	n/a
Short Previous Month	n/a
Short % of Shares Out	n/a
Short % of Float	n/a
Short Ratio (days to cover)	n/a

Income Statement

In the last 12 months, Transgene had revenue of GBP 6.49 million and -31.53 million in losses. Loss per share was -0.24.

Revenue	6.49M
Gross Profit	-25.02M
Operating Income	-31.05M
Pretax Income	-31.53M
Net Income	-31.53M
EBITDA	-29.91M
EBIT	-31.05M
Loss Per Share	-0.24

Full Income Statement

Balance Sheet

The company has 14.38 million in cash and 26.63 million in debt, with a net cash position of -12.25 million.

Cash & Cash Equivalents	14.38M
Total Debt	26.63M
Net Cash	-12.25M
Net Cash Per Share	n/a
Equity (Book Value)	-3.09M
Book Value Per Share	-0.02
Working Capital	-15.82M

Full Balance Sheet

Cash Flow

In the last 12 months, operating cash flow was -19.68 million and capital expenditures -1.15 million, giving a free cash flow of -20.83 million.

Operating Cash Flow	-19.68M
Capital Expenditures	-1.15M
Free Cash Flow	-20.83M
FCF Per Share	n/a

Full Cash Flow Statement

Margins

Gross Margin	n/a
Operating Margin	-478.15%
Pretax Margin	-485.56%
Profit Margin	n/a
EBITDA Margin	n/a
EBIT Margin	n/a
FCF Margin	n/a

Dividends & Yields

Transgene does not appear to pay any dividends at this time.

Dividend Per Share	n/a
Dividend Yield	n/a
Dividend Growth (YoY)	n/a
Years of Dividend Growth	n/a
Payout Ratio	n/a
Buyback Yield	-30.91%
Shareholder Yield	-30.91%
Earnings Yield	-15.70%
FCF Yield	-10.37%

Fair Value

There are several formulas that can be used to estimate the intrinsic value of a stock.

Lynch Fair Value	n/a
Lynch Upside	n/a
Graham Number	n/a
Graham Upside	n/a

Stock Splits

This stock does not have any record of stock splits.

Last Split Date	n/a
Split Type	n/a
Split Ratio	n/a

Scores

Transgene has an Altman Z-Score of -3.81 and a Piotroski F-Score of 4. A Z-score under 3 suggests an increased risk of bankruptcy.

Altman Z-Score	-3.81
Piotroski F-Score	4